Alkermes (ALKS) reported revenue growth of 7% per year, trailing the broader US market average of 10.2% annually. Net profit margins came in at 22.2%, down from last year’s 25.7%. Earnings are projected to decline at an average rate of 11.1% per year over the next three years. Despite the cautious near-term outlook, the company’s five-year record shows it has become profitable, with historical earnings growth averaging 56.4% per year and a consistent track of high-quality earnings that value-focused investors may find compelling.

See our full analysis for Alkermes.

Next, we will weigh Alkermes’s headline numbers against the dominant narratives in the market to see which themes the latest results reinforce or call into question.

Wide Analyst Disagreement on $44.00 Price Target

• While Alkermes's current share price sits at $31.45, analysts collectively assign a price target of $44.00, which is about 40% higher. This is despite a consensus that earnings will drop from $348.1 million to $169.0 million over five years.
• Analysts' consensus view is that top-line growth and commercial execution in neuroscience products provide support for this valuation.
  • Expanding demand for proprietary drugs is anticipated to fuel revenue, while growing leverage from cost discipline supports flexibility for new pipeline investments.
  • However, projected margin compression from 23.1% to 11.7% by 2028 and high variance in individual analyst earnings forecasts, which range from $291.5 million to negative $60.5 million, underscore that this price target depends on believing in multiple future catalysts. This comes even as short-term earnings momentum is weak.
• For a summary of the full range of consensus narrative and what it means for Alkermes, see what the community is saying about Alkermes.

Margin Forecast Signals Shrinking Profitability

• Profit margins are projected to decrease sharply from 23.1% today to just 11.7% in three years, according to consensus estimates.
• Consensus narrative highlights the tension between Alkermes' focus on margin expansion from cost control and new product launches.
  • Analysts point to a disciplined cost structure post-divestiture as a factor expected to offset some margin strain from escalating R&D spend on orexin agonist trials and potential product launches.
  • Bears warn that a shrinking portfolio concentrated on Vivitrol, Aristada, and Lybalvi leaves the company vulnerable to generic competition and regulatory shifts, which could erode profitability faster than expected.

Valuation Discount Versus Industry May Not Last

• Alkermes trades at a Price-to-Earnings ratio of 15.4x, well below industry (17.9x) and peer (36.3x) averages, even though future profits are forecast to contract instead of grow.
• Consensus narrative notes this value gap could attract bargain hunters given the recent five-year streak of profitability.
  • Alkermes sits below DCF fair value of $38.30, suggesting upside for those willing to look past near-term headwinds.
  • However, the risk that both margins and revenue lag the market means Alkermes' current value status could reverse quickly if growth and profitability disappoint further.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Alkermes on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Have a different interpretation of the figures? In just a few minutes, you can create your own narrative and share how you see things. Do it your way

A great starting point for your Alkermes research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

See What Else Is Out There

Alkermes faces shrinking profit margins, inconsistent earnings forecasts, and lacks the steady growth profile that some investors prioritize for long-term security.

Want more reliable results? Filter for stable growth stocks screener (2121 results) to find companies that are consistently increasing sales and profits, so you can invest in steadier performers with clearer outlooks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.